Compare RNP & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNP | TRAX |
|---|---|---|
| Founded | 2003 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 1.2B |
| IPO Year | N/A | 2026 |
| Metric | RNP | TRAX |
|---|---|---|
| Price | $18.42 | $44.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 136.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.01 | $15.69 |
| 52 Week High | $21.88 | $49.91 |
| Indicator | RNP | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 67.17 |
| Support Level | $18.01 | $40.72 |
| Resistance Level | $20.82 | $48.94 |
| Average True Range (ATR) | 0.28 | 3.25 |
| MACD | 0.06 | 1.55 |
| Stochastic Oscillator | 65.36 | 99.59 |
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.